NCT03087019View on ClinicalTrials.gov

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

August 4, 2020

Study Completion Date

August 4, 2020

Conditions

Adenoid Cystic Carcinoma

Interventions

RADIATION

Radiation

Standard use of radiation is administered

DRUG

Pembrolizumab

Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.

Trial Locations (2)

02062

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03087019 - Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Biotech Hunter | Biotech Hunter